Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to ...

Experts say the drug will give thousands of vulnerable infants “their own suit of armour” for their first winter ...

Like nirsevimab, it’s an antibody that can reduce infections with the virus—but unlike nirsevimab, which is just a single shot, palivzumab requires monthly injections throughout the RSV season.

Meanwhile, 0.1% of infants in the nirsevimab group and 0.5% of infants in the standard care group were hospitalized for very severe RSV-associated lower respiratory tract infection, with an ...

Amid an ongoing shortage of nirsevimab, an RSV immunization for young children, the US Centers for Disease Control and Prevention has announced that more than 77,000 additional doses will be ...

Nirsevimab demonstrated protectionagainst respiratory syncytial virus diseasein healthy infants in Phase 3 trial PARIS– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial ...

The new injection, Nirsevimab, will be given to high-risk babies, including those born too early to be protected by the RSV ...